Cargando…

Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab

The objective of the study was to evaluate whether Point-of-Care (POC) assays are equivalent to ELISAs for measuring residual trough levels of adalimumab (ADA) in a cohort of Inflammatory Bowel Disease (IBD) patients. ADA trough levels obtained by POC assays were used to optimize patients in daily c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherry, Mohamad, Dutzer, Dominique, Nasser, Yara, Berger, Anne-Emmanuelle, Roblin, Xavier, Paul, Stephane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565289/
https://www.ncbi.nlm.nih.gov/pubmed/32854232
http://dx.doi.org/10.3390/jcm9092739
_version_ 1783595900122169344
author Cherry, Mohamad
Dutzer, Dominique
Nasser, Yara
Berger, Anne-Emmanuelle
Roblin, Xavier
Paul, Stephane
author_facet Cherry, Mohamad
Dutzer, Dominique
Nasser, Yara
Berger, Anne-Emmanuelle
Roblin, Xavier
Paul, Stephane
author_sort Cherry, Mohamad
collection PubMed
description The objective of the study was to evaluate whether Point-of-Care (POC) assays are equivalent to ELISAs for measuring residual trough levels of adalimumab (ADA) in a cohort of Inflammatory Bowel Disease (IBD) patients. ADA trough levels obtained by POC assays were used to optimize patients in daily clinical practice. Different assays (three ELISAs (Enzyme-Linked ImmunoSorbent Assay) from two different suppliers and two POC assays) were compared to measure ADA trough levels in a first cohort of 31 IBD patients. All assays revealed a high correlation within the assays, ranging from 0.86 to 0.99. Cut-off values were always higher with ELISAs than with POC assays. Then, a small prospective clinical study with a second cohort of 37 IBD patients was performed to compare POC assays and ELISAs for their ability to optimize patients on the basis of the measured ADA trough levels. The use of a POC assay to monitor ADA trough levels did not improve the follow-up of patients with loss of response, as they were always optimized whatever their ADA residual rate. For patients in clinical remission, a POC assay can be useful in some clinical situations to maintain or de-escalate ADA doses according to the measured trough levels. In conclusion, different assays for ADA monitoring are quite equivalent. A POC assay could be only useful for a proactive strategy for asymptomatic patients with a sub-therapeutic dose of ADA, but new therapeutic thresholds need to be identified.
format Online
Article
Text
id pubmed-7565289
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75652892020-10-26 Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab Cherry, Mohamad Dutzer, Dominique Nasser, Yara Berger, Anne-Emmanuelle Roblin, Xavier Paul, Stephane J Clin Med Article The objective of the study was to evaluate whether Point-of-Care (POC) assays are equivalent to ELISAs for measuring residual trough levels of adalimumab (ADA) in a cohort of Inflammatory Bowel Disease (IBD) patients. ADA trough levels obtained by POC assays were used to optimize patients in daily clinical practice. Different assays (three ELISAs (Enzyme-Linked ImmunoSorbent Assay) from two different suppliers and two POC assays) were compared to measure ADA trough levels in a first cohort of 31 IBD patients. All assays revealed a high correlation within the assays, ranging from 0.86 to 0.99. Cut-off values were always higher with ELISAs than with POC assays. Then, a small prospective clinical study with a second cohort of 37 IBD patients was performed to compare POC assays and ELISAs for their ability to optimize patients on the basis of the measured ADA trough levels. The use of a POC assay to monitor ADA trough levels did not improve the follow-up of patients with loss of response, as they were always optimized whatever their ADA residual rate. For patients in clinical remission, a POC assay can be useful in some clinical situations to maintain or de-escalate ADA doses according to the measured trough levels. In conclusion, different assays for ADA monitoring are quite equivalent. A POC assay could be only useful for a proactive strategy for asymptomatic patients with a sub-therapeutic dose of ADA, but new therapeutic thresholds need to be identified. MDPI 2020-08-25 /pmc/articles/PMC7565289/ /pubmed/32854232 http://dx.doi.org/10.3390/jcm9092739 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cherry, Mohamad
Dutzer, Dominique
Nasser, Yara
Berger, Anne-Emmanuelle
Roblin, Xavier
Paul, Stephane
Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab
title Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab
title_full Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab
title_fullStr Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab
title_full_unstemmed Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab
title_short Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab
title_sort point-of-care assays could be useful for therapeutic drug monitoring of ibd patients in a proactive strategy with adalimumab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565289/
https://www.ncbi.nlm.nih.gov/pubmed/32854232
http://dx.doi.org/10.3390/jcm9092739
work_keys_str_mv AT cherrymohamad pointofcareassayscouldbeusefulfortherapeuticdrugmonitoringofibdpatientsinaproactivestrategywithadalimumab
AT dutzerdominique pointofcareassayscouldbeusefulfortherapeuticdrugmonitoringofibdpatientsinaproactivestrategywithadalimumab
AT nasseryara pointofcareassayscouldbeusefulfortherapeuticdrugmonitoringofibdpatientsinaproactivestrategywithadalimumab
AT bergeranneemmanuelle pointofcareassayscouldbeusefulfortherapeuticdrugmonitoringofibdpatientsinaproactivestrategywithadalimumab
AT roblinxavier pointofcareassayscouldbeusefulfortherapeuticdrugmonitoringofibdpatientsinaproactivestrategywithadalimumab
AT paulstephane pointofcareassayscouldbeusefulfortherapeuticdrugmonitoringofibdpatientsinaproactivestrategywithadalimumab